These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 23432516)
1. Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors. Sakkiah S; Arullaperumal V; Hwang S; Lee KW J Enzyme Inhib Med Chem; 2014 Feb; 29(1):69-80. PubMed ID: 23432516 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors. Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124 [TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Vyas VK; Ghate M; Goel A J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Sakkiah S; Thangapandian S; John S; Lee KW Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051 [TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors. Sakkiah S; Lee KW Acta Pharmacol Sin; 2012 Jul; 33(7):964-78. PubMed ID: 22684028 [TBL] [Abstract][Full Text] [Related]
6. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors. Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012 [TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors. Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425 [TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors. Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317 [TBL] [Abstract][Full Text] [Related]
9. Ligand and structure-based approaches for the identification of SIRT1 activators. Vyas VK; Goel A; Ghate M; Patel P Chem Biol Interact; 2015 Feb; 228():9-17. PubMed ID: 25595223 [TBL] [Abstract][Full Text] [Related]
10. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it. Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640 [TBL] [Abstract][Full Text] [Related]
11. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418 [TBL] [Abstract][Full Text] [Related]
12. Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent cathepsin D inhibitors. Sakkiah S; Thangapandian S; Lee KW Chem Biol Drug Des; 2012 Jul; 80(1):64-79. PubMed ID: 22269155 [TBL] [Abstract][Full Text] [Related]
13. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors. Saxena S; Chaudhaery SS; Varshney K; Saxena AK SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581 [TBL] [Abstract][Full Text] [Related]
14. In Silico Study Probes Potential Inhibitors of Human Dihydrofolate Reductase for Cancer Therapeutics. Rana RM; Rampogu S; Zeb A; Son M; Park C; Lee G; Yoon S; Baek A; Parameswaran S; Park SJ; Lee KW J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30754680 [TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415 [TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2. Sakkiah S; Thangapandian S; Lee KW J Mol Model; 2012 Jul; 18(7):3267-82. PubMed ID: 22249747 [TBL] [Abstract][Full Text] [Related]
17. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. Lange G; Lesuisse D; Deprez P; Schoot B; Loenze P; Bénard D; Marquette JP; Broto P; Sarubbi E; Mandine E J Med Chem; 2003 Nov; 46(24):5184-95. PubMed ID: 14613321 [TBL] [Abstract][Full Text] [Related]
18. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors. Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel acyl coenzyme a: cholesterol acyltransferase inhibitors: pharmacophore-based virtual screening, synthesis and pharmacology. Chhabria MT; Brahmkshatriya PS; Mahajan BM; Darji UB; Shah GB Chem Biol Drug Des; 2012 Jul; 80(1):106-13. PubMed ID: 22429570 [TBL] [Abstract][Full Text] [Related]